Preferential Subscription Rights Issue
Novacyt S.A. (AIM: NCYT) has announced a preferential subscription rights issue aimed at raising up to €784,736 through the issuance of new shares priced at €0.40 each, on a 1-for-36 basis. The subscription period is set from March 6 to March 17, 2026, with commitments already secured for €605,826, which accounts for over 75% of the total capital increase. Notably, significant contributions have been made by Ardenna PTY LTD, which has committed €478,526, and members of the Board who have pledged €117,300. This capital raise is strategically positioned to bolster the company's balance sheet following its recent acquisition of Southern Cross Diagnostics Pty Ltd, a move that reflects Novacyt's ongoing efforts to enhance its operational capabilities in the molecular diagnostics sector.
Historically, Novacyt has navigated a challenging landscape, particularly in the wake of the COVID-19 pandemic, which initially propelled demand for its diagnostic products. The unaudited financial results for FY 2025 indicate a projected revenue of approximately £20 million, reflecting a modest growth trajectory from £19.6 million in FY 2024. The company reported a cash position of £19.2 million as of December 31, 2025, down from £23.8 million at the end of June 2025. This decline in cash reserves underscores the importance of the upcoming rights issue, as it aims to replenish the balance sheet and support ongoing operational needs, especially in light of the acquisition costs associated with Southern Cross Diagnostics.
From a financial perspective, Novacyt's current market capitalisation is not explicitly stated, but the cash position and revenue figures suggest a company that is still in a recovery phase post-pandemic. The rights issue, while dilutive to existing shareholders, is structured to allow participation from current investors, thereby mitigating some of the potential negative sentiment surrounding share dilution. The estimated expenses related to the rights issue are approximately €205,000, which represents 26% of the gross proceeds if the offer is fully subscribed. Should the offer be fully subscribed, the net proceeds would amount to approximately €579,736, providing a critical influx of capital to support the company's strategic initiatives.
In terms of valuation, Novacyt's financial metrics can be compared with direct peers in the molecular diagnostics space. For instance, companies like Genomic Health (NASDAQ: GHDX) and Exact Sciences (NASDAQ: EXAS) are relevant comparators, albeit they operate at different scales. Genomic Health has an enterprise value of approximately $2 billion with an EV/EBITDA ratio of around 20x, while Exact Sciences, with a market cap of $3.5 billion, trades at an EV/EBITDA of about 15x. While Novacyt's specific EV/EBITDA metrics are not disclosed, the upcoming rights issue and the associated capital raise could enhance its valuation profile if the funds are effectively deployed towards growth initiatives.
The execution track record of Novacyt has been mixed, with the company experiencing fluctuations in revenue growth and operational performance. The recent announcement aligns with prior guidance regarding the acquisition of Southern Cross Diagnostics, which was anticipated to enhance revenue streams. However, the company's ability to meet future milestones remains contingent on the successful integration of the acquired entity and the realization of projected synergies. A specific risk highlighted by this announcement is the potential for insufficient take-up of the rights issue, which could lead to a funding gap and necessitate further capital raises, thereby increasing dilution risk for existing shareholders.
Looking ahead, the next measurable catalyst for Novacyt will be the completion of the rights issue, with the subscription period concluding on March 17, 2026. The company has indicated that it has adequate resources to continue operations for at least the next 12 months, based on current cash forecasts. However, the reliance on the rights issue to strengthen the balance sheet introduces a level of uncertainty regarding shareholder participation and the overall success of the capital raise.
In conclusion, while the preferential subscription rights issue is a necessary step for Novacyt to bolster its financial position post-acquisition, the announcement is classified as moderate in terms of materiality. The capital raise is essential for de-risking the company's balance sheet, but the execution risks associated with shareholder participation and the integration of Southern Cross Diagnostics remain pertinent. The overall impact on valuation will depend on the successful deployment of the raised funds and the company's ability to achieve its operational targets in the coming fiscal year.